Summary:
- This article discusses the development of a new bispecific antibody drug candidate called HLX14, which is being developed by Henlius Biotech, a biopharmaceutical company.
- Bispecific antibodies are a type of therapeutic that can bind to two different targets, potentially leading to more effective treatments for various diseases.
- The article highlights the successful completion of the first-in-human clinical trial for HLX14, which is an important step in the drug development process and could pave the way for further research and potential approval of the drug.